{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:03:24Z","timestamp":1789517004084,"version":"build-2803163510"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Severe pulmonary sarcoidosis is less common in Japan than in other countries, and the actual clinical situation of systemic steroid use in Japan requires clarification.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study analyzed 65 patients with histologically diagnosed sarcoidosis who initially received systemic steroids for pulmonary lesions and made regular outpatient visits to Hokkaido University Hospital, JR Sapporo Hospital, or JR Tokyo General Hospital in September 2017.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Median age at diagnosis was 35 (interquartile range [IQR] 26\u201348) years. Thirty-four patients (52.3%) were men. Median time from diagnosis to steroid initiation was 5 (IQR, 1\u20139) years. Median maximum steroid dose was prednisolone (PSL) 30 (range 5\u201360) mg\/day. Immunosuppressants were used in 19 patients (29.2%). Twenty-one patients (32.3%) received PSL\u202f\u2264\u202f10\u202fmg\/day and 7 (10.8%) received 5\u202fmg\/day. The PSL\u202f\u2264\u202f10\u202fmg\/day group included a significantly lower proportion of men than the group treated with higher doses (33.3% vs. 61.4%, <jats:italic>p<\/jats:italic>\u202f=\u202f0.034). Most cases were effectively treated, but some required long-term steroid administration. Even when steroid inhalation therapy was ineffective, systemic administration of PSL 5\u202fmg\/day effectively resolved chest imaging findings and respiratory symptoms. The successful steroid withdrawal rate was 18.5% overall, increasing to 23.8 and 42.9% in the PSL\u202f\u2264\u202f10\u202fmg\/day and 5\u202fmg\/day groups, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Approximately one-third of patients received an initial steroid dose of PSL\u202f\u2264\u202f10\u202fmg\/day for pulmonary sarcoidosis. This was mostly effective and the withdrawal rate was relatively high. Our results support that some Japanese patients with pulmonary sarcoidosis may successfully receive an initial dose of PSL\u202f\u2264\u202f10\u202fmg\/day.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1567334","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T05:42:48Z","timestamp":1748583768000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical characteristics of patients with pulmonary sarcoidosis treated with systemic steroids in Japan"],"prefix":"10.3389","volume":"12","author":[{"given":"Michiru","family":"Sawahata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Tamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Bando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Maemondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kawanobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiyoko","family":"Kono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriharu","family":"Shijubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Konno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"ref1","first-page":"222","article-title":"Clinical characteristics of 195 Japanese sarcoidosis patients treated with oral corticosteroids","volume":"20","author":"Sugisaki","year":"2003","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.ccm.2008.03.006","article-title":"Outcome of sarcoidosis","volume":"29","author":"Nagai","year":"2008","journal-title":"Clin Chest Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1111\/resp.13105","article-title":"Resolution rate of pulmonary sarcoidosis and its related factors in a Japanese population","volume":"22","author":"Hattori","year":"2017","journal-title":"Respirology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S0140-6736(67)90493-X","article-title":"Treatment of sarcoidosis. Report of a controlled therapeutic trial","volume":"290","author":"James","year":"1967","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1164\/arrd.1973.107.4.609","article-title":"A controlled trial of prednisone treatment of sarcoidosis","volume":"107","author":"Israel","year":"1973","journal-title":"Am Rev Respir Dis"},{"key":"ref6","first-page":"49","article-title":"Erster Bericht \u00fcber eine kontrollierte klinische Untersuchung zur Prednisolon-Behandlung der thorakalen Sarkoidose","volume":"142","author":"Roth","year":"1975","journal-title":"Z Erkr Atmungsorgane"},{"key":"ref7","first-page":"215","article-title":"Corticosteroid therapy of pulmonary sarcoidosis. A prospective evaluation of alternate day and daily dosage in stage II disease","volume":"60","author":"Selroos","year":"1979","journal-title":"Scand J Respir Dis"},{"key":"ref8","first-page":"496","article-title":"Corticosteroid therapy in sarcoidosis. A five-year, controlled follow-up study","volume":"87","author":"Zaki","year":"1987","journal-title":"NY State J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1378\/chest.116.2.424","article-title":"Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled multicenter study","volume":"116","author":"Pietinalho","year":"1999","journal-title":"Chest"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1378\/chest.121.1.24","article-title":"Early treatment of stage II sarcoidosis improves 5-year pulmonary function","volume":"121","author":"Pietinalho","year":"2002","journal-title":"Chest"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"CD001114","DOI":"10.1002\/14651858.CD001114.pub2","article-title":"Corticosteroids for pulmonary sarcoidosis","volume":"2010","author":"Paramothayan","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1164\/ajrccm.160.2.ats4-99","article-title":"Statement on sarcoidosis. Joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999","volume":"160","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"190146","DOI":"10.1183\/16000617.0146-2019","article-title":"Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis","volume":"29","author":"Rahaghi","year":"2020","journal-title":"Eur Respir Rev"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/thoraxjnl-2019-214348","article-title":"BTS clinical statement on pulmonary sarcoidosis","volume":"76","author":"Thillai","year":"2021","journal-title":"Thorax"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2004079","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur Respir J"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2300198","DOI":"10.1183\/13993003.00198-2023","article-title":"High-dose (40 mg) versus low-dose (20 mg) prednisolone for treating sarcoidosis: a randomised trial (SARCORT trial)","volume":"62","author":"Dhooria","year":"2023","journal-title":"Eur Respir J"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.rmed.2017.12.009","article-title":"Steroids for sarcoidosis: how much and for how long?","volume":"138","author":"Baughman","year":"2018","journal-title":"Respir Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1183\/09031936.00156314","article-title":"Negative clinical trials in sarcoidosis: failed therapies or flawed study design?","volume":"44","author":"Moller","year":"2014","journal-title":"Respir J"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/17476348.2020.1707672","article-title":"Knowing when to use steroids, immunosuppressants or biologics for the treatment of sarcoidosis","volume":"14","author":"Pande","year":"2020","journal-title":"Expert Rev Respir Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1183\/09031936.00138913","article-title":"Relapses of sarcoidosis: what are they and can we predict who will get them?","volume":"43","author":"Baughman","year":"2014","journal-title":"Eur Respir J"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.rdc.2015.08.012","article-title":"Corticosteroids in sarcoidosis","volume":"42","author":"Judson","year":"2016","journal-title":"Rheum Dis Clin N Am"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"106564","DOI":"10.1016\/j.rmed.2021.106564","article-title":"The impact of demographic disparities in the presentation of sarcoidosis: a multicenter prospective study","volume":"187","author":"Zhou","year":"2021","journal-title":"Respir Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.7878\/jjsogd.33.123","article-title":"Case of pulmonary sarcoidosis with bronchovascular bundle lesions and cavity improved with low dose corticosteroid therapy","volume":"33","author":"Sijubo","year":"2013","journal-title":"JJSOG"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e2022018","DOI":"10.36141\/svdld.v39i2.12995","article-title":"Imaging findings of fibrosis in pulmonary sarcoidosis","volume":"39","author":"Sawahata","year":"","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref25","first-page":"105","article-title":"Views on the treatment of sarcoidosis-2003","volume":"23","year":"2003","journal-title":"JJSOG"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"991783","DOI":"10.3389\/fmed.2022.991783","article-title":"Sarcoidosis: updates on therapeutic drug trials and novel treatment approaches","volume":"9","author":"Obi","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"ref27","volume-title":"The Japanese Society of Sarcoidosis and Other Granulomatous Disorders (JSSOG) diagnostic standard and guideline for Sarcoidosis-2023","year":"2023"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1378\/chest.111.3.623","article-title":"Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy","volume":"111","author":"Gottlieb","year":"1997","journal-title":"Chest"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1164\/ajrccm.149.4.8143052","article-title":"Outcome of the treatment for sarcoidosis","volume":"149","author":"Hunninghake","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"key":"ref30","first-page":"275","article-title":"Features of sarcoidosis associated with chronic disease","volume":"31","author":"Baughman","year":"2015","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref31","first-page":"112","article-title":"An epidemiological perspective on the pathology and etiology of sarcoidosis","volume":"33","author":"Sawahata","year":"2016","journal-title":"Sarcoidosis Vasc Dis"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-019-0096-x","article-title":"Sarcoidosis","volume":"5","author":"Grunewald","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"545413","DOI":"10.3389\/fimmu.2020.545413","article-title":"Treatment of sarcoidosis: a multidisciplinary approach","volume":"11","author":"Gerke","year":"2020","journal-title":"Front Immunol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"9440","DOI":"10.1038\/s41598-018-27554-3","article-title":"Nationwide survey on the organ-specific prevalence and its interaction with sarcoidosis in Japan","volume":"8","author":"Hattori","year":"2018","journal-title":"Sci Rep"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1183\/09031936.00005414","article-title":"Age-related differences in chest radiographic staging of sarcoidosis in Japan","volume":"43","author":"Sawahata","year":"2014","journal-title":"Eur Respir J"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1183\/09031936.00075307","article-title":"Epidemiology of sarcoidosis in Japan","volume":"31","author":"Morimoto","year":"2008","journal-title":"Eur Respir J"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1567334\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T05:42:50Z","timestamp":1748583770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1567334\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":36,"alternative-id":["10.3389\/fmed.2025.1567334"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1567334","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"article-number":"1567334"}}